MHE Week in Review - Mpox, RSV and More

In a meta-analysis of 57 studies, Zolgensma achieved a 95% survival rate and reduced the number of patients requiring ventilatory support.

Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.

Effective July 1, 2025, this agreement ensures that nearly 400,000 patients covered by IBX each year will keep receiving quality care from Penn Medicine providers. The partnership focuses on improving health outcomes, patient experiences, and controlling costs, aiming to set new standards for innovative care in healthcare, according to a release.

In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.

The researchers hope their discoveries will lead to novel strategies to not just slow fibrosis but promote functional repair of the injured lung.

The FDA has accepted a new drug application for aficamten, a new obstructive hypertrophic cardiomyopathy drug. A goal date has been set for Sept. 26, 2025.